Shifting the paradigm for early cancer detection

Wednesday, September 20th, 2023 | 12:00 PM - 1:00 PM CT

Current guidelines recommend routine screening for only four cancer types. Two-thirds of incident cancers have no recommended screening options.1* In addition, a significant portion of cancer cases are being detected in later stages, where treatment options may be more limited.1,2 In response to these gaps in cancer screening, early detection blood tests designed to detect multiple biomarkers associated with many types of cancer are being developed to help detect cancer prior to symptom onset.3 

In this session Dr. Tomasz Beer, a globally recognized expert in early cancer detection, will discuss how multi-cancer early detection (MCED) test might help detect more cancers earlier and the growing evidence in support of an MCED test in development. 

You'll learn:
  • What is MCED testing and how it may help shift the paradigm in cancer screening
  • Longitudinal analysis from DETECT-A, the first-ever prospective study of an MCED test
  • Details on a multi-biomarker class approach for an MCED test that is in development 



Tomasz Beer - Sarah Simon Cropped

Tomasz Beer, MD, FACP

Chief Medical Officer, VP of Multi-Cancer Early Detection, Exact Sciences and Adjunct Professor of Medicine, OHSU Knight Cancer Institute

* US data, calculated using estimated new diagnoses and deaths from cancers that have standard of care screening: breast, cervical, colorectal and lung (high risk) against all sites 


1. Siegel RL, et al. CA Cancer J Clin. 2023.

2. Kakushadze Z, et al. Data. 2017.

3. Cohen JD, et al. Science. 2018.